ReviewMedical oncology (Northwood, London, England)2012
Primary neuroendocrine breast cancer, how much do we know so far?
Review in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Article
- Radiological and Histopathological Predictors of Survival in Neuroendocrine Differentiated Breast Cancer: A Comparative Analysis with NS-IDC.Breast cancer (Dove Medical Press) · 2026Article
- Postoperative recurrence and systemic metastasis of large cell neuroendocrine carcinoma of the breast: a case report including T-DXd treatment.Frontiers in oncology · 2026Article
- Primary Large-Cell Neuroendocrine Carcinoma of the Breast.Diagnostics (Basel, Switzerland) · 2024Article
- Neuroendocrine breast carcinoma.Autopsy & case reports · 2024Article
- Breast Metastasis Arising from Ileal Neuroendocrine Tumor: an Unusual Presentation.Nuclear medicine and molecular imaging · 2023Article
- Primary Breast Small Cell Carcinoma With Merkel Cell Features: A Case Report and Literature Review.Journal of breast cancer · 2023Article
- HER-2-positive primary neuroendocrine neoplasms of the breast with signet ring feature: A case report and review of literature.Frontiers in oncology · 2022Review
- Neuroendocrine breast carcinoma: a rare but challenging entity.Medical oncology (Northwood, London, England) · 2020Review
- Neuroendocrine Cancer of the Breast: A Rare Entity.Journal of clinical medicine · 2020Review
- Primary Neuroendocrine Neoplasms of the Breast: Still Open Issues.Frontiers in endocrinology · 2020Review
- Rare epithelial breast cancer: surgery and adjuvant therapy.Translational cancer research · 2019Review
- HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature.Breast care (Basel, Switzerland) · 2016Article
- Primary Large-Cell Neuroendocrine Carcinoma of the Breast Occurring in a Pre-Menopausal Woman.Breast care (Basel, Switzerland) · 2015Article
- Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.The oncologist · 2014Article
- Primary small-cell neuroendocrine carcinoma of the male breast: a rare case report with review of the literature.OncoTargets and therapy · 2014Article
- Neuroendocrine carcinoma of breast: a rare case vignette.Journal of clinical and diagnostic research : JCDR · 2013Article
- Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature.World journal of surgical oncology · 2013Article
- Primary neuroendocrine breast carcinoma: a case report and literature review.Radiologia brasileiraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary neuroendocrine cancer of the breast (NECB) is an extremely rare tumor. In 2003, the World Health Organization (WHO) recognized this category with three well-described subtypes: small cell, large cell, and carcinoid-like carcinoma; very few peer-review publications based on the WHO definition were encountered in the literature, and we conducted a literature search to investigate the reported incidence, diagnosis, prognosis, hormone receptor status, and treatment options for this rare tumor. Confirming the breast as an origin of neuroendocrine tumor represents a challenge. The diagnosis is mainly dependent on the exclusion of other extra-mammary organs based on clinical, radiological, and pathological data. Except for the very rare type small cell carcinoma, estrogen and progesterone receptors were reported to be expressed in 90 and 83% of NECB, respectively. It is hypothesized that primary breast neuroendocrine carcinoma differentiates from the epithelial cells during the carcinogenesis process; the prognosis of non-small cell primary NECB seems to improve as the amount of mucinous component increases in the tumor specimen. Management similar to interventions utilized to manage the usual ductal-type carcinoma has been attempted in the past, such as chemotherapy and hormonal therapy; however, due to the rarity of the tumor, none of the published studies are randomized nor do they have a large number of patients. Additionally, none of reports analyzed NECB based on its distinct subtypes. These limitations make recommendations largely based on anecdotal and small observatory studies and call for the need for further research in this extremely rare tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.